Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1α signaling

Experimental Biology and Medicine

Volumn 233, Issue 10, 2008, Pages 1222-1230

  Caretti, Anna ^a,b   Bianciardi, Paola ^a   Ronchi, Raffaella ^a   Fantacci, Monica ^a   Guazzi, Marco ^a   Samaja, Michele ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Istituto Nazionale Per le Ricerche Cardiovascolari (INRC)   (Italy)

Author keywords

Bcl 2; Chronic hypoxia; HIF l ; Hypoxia signaling; NO

Indexed keywords

CYCLIC GMP; DNA NUCLEOTIDYLEXOTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PHOSPHODIESTERASE V; PROTEIN BAX; PROTEIN BCL 2; SILDENAFIL; HIF1A PROTEIN, MOUSE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN BIOPSY; BRAIN CORTEX; BRAIN HYPOXIA; BRAIN NERVE CELL; BRAIN WEIGHT; CELL HYPOXIA; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IMMUNOFLUORESCENCE; IN VIVO STUDY; MALE; MOUSE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE LEVEL; ANIMAL; ANIMAL MODEL; ANOXIA; DRUG ANTAGONISM; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; ANOXIA; APOPTOSIS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED ICR; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, ANIMAL; NEURONS; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SIGNAL TRANSDUCTION; SULFONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54549112294     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0802-RM-73     Document Type: Article

References (47)

1. Semenza G. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8:S62-S67, 2002.
2. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-669, 2005.
3. 2-regulated prolyl hydroxylation. Science 292:468-472, 2001.
4. Stroka D, Burkhardt T, Desbaillets I, Wenger R, Neil D, Bauer C, Gassmann M, Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15:2445-2453, 2001.
5. Bianciardi P, Fantacci M, Caretti A, Ronchi R, Milano G, Morel S, von Segesser L, Corno A, Samaja M. Chronic in vivo hypoxia in various organs: hypoxia-inducible factor-1alpha and apoptosis. Biochem Biophys Res Commun 342:875-880, 2006.
6. Fantacci M, Bianciardi P, Caretti A, Coleman TR, Cerami A, Brines M, Samaja M. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci U S A 103:17531-17536, 2006.
7. Caretti A, Morel S, Milano G, Fantacci M, Bianciardi P, Ronchi R, Vassalli G, von Segesser LK, Samaja M. Heart HIF-1alpha and MAP kinases during hypoxia: are they associated in vivo? Exp Biol Med (Maywood) 232:887-894, 2007.
8. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia- induced pulmonary hypertension. Circulation 107:3230-3235, 2003.
9. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 83:576-582, 1999.
10. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 287:719-725, 2002.
11. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 40:2006-2012, 2002.
12. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595-597, 2003.
13. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 141:169-177, 2004.
14. Aldashev AA, Kojonazarov BK, Amatov TA, Sooronbaev TM, Mirrakhimov MM, Morrell NW, Wharton J, Wilkins MR. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 60:683-687, 2005.
15. Richalet JP, Gratadour P, Robach P, Pham I, Dechaux M, Joncquiert-Latarjet A, Mollard P, Brugniaux J, Cornolo J. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 171:275-281, 2005.
16. Hsu AR, Barnholt KE, Grundmann NK, Lin JH, McCallum SW, Friedlander AL. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol 100:2031-2040, 2006.
17. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50:2136-2144, 2007.
18. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610, 2005.
19. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955, 2005.
20. Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, Meng H, Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 36:847-852, 2005.
21. Zhang RL, Zhang Z, Zhang L, Wang Y, Zhang C, Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 83:1213-1219, 2006.
22. Corno AF, Milano G, Samaja M, Tozzi P, von Segesser LK. Chronic hypoxia: a model for cyanotic congenital heart defects. J Thorac Cardiovasc Surg 124:105-112, 2002.
23. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, Fisher PW, Wittkamp M, Hawkins J, Chou E, Kukreja AK, Wang X, Marwaha VR, Xi L. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol 42:219-232, 2005.
24. Guazzi M, Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 14:1893-1910, 2007.
25. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:297-310, 1999.
26. Milano G, Corno AF, Lippa S, Von Segesser LK, Samaja M. Chronic and intermittent hypoxia induce different degrees of myocardial tolerance to hypoxia-induced dysfunction. Exp Biol Med (Maywood) 227:389-397, 2002.
27. Nakamizo T, Kawamata J, Yoshida K, Kawai Y, Kanki R, Sawada H, Kihara T, Yamashita H, Shibasaki H, Akaike A, Shimohama S. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res 71:485-495, 2003.
28. Williams BA, Liu C, Deyoung L, Brock GB, Sims SM. Regulation of intracellular Ca2+ release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. Am J Physiol Cell Physiol 288:C650-C658, 2005.
29. Thippeswamy T, McKay JS, Quinn JP, Morris R. Nitric oxide, a biological double-faced janus-is this good or bad? Histol Histopathol 21:445-458, 2006.
30. Osuka K, Watanabe Y, Usuda N, Nakazawa A, Tokuda M, Yoshida J. Modification of endothelial NO synthase through protein phosphorylation after forebrain cerebral ischemia/reperfusion. Stroke 35:2582-2586, 2004.
31. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 25:915-922, 2005.
32. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, Darley-Usmar VM, Gladwin MT. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res 100:654-661, 2007.
33. Ciani E, Guidi S, Bartesaghi R, Contestabile A. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J Neurochem 82:1282-1289, 2002.
34. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26:2027-2038, 2007.
35. Jones NM, Bergeron M. Hypoxia-induced ischemic tolerance in neonatal rat brain involves enhanced ERK1/2 signaling. J Neurochem 89:157-167, 2004.
36. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, Thorner PS, Shibuya M, Malkin D, Baruchel S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65: 7267-7275, 2005.
37. Melani A, Gianfriddo M, Vannucchi MG, Cipriani S, Baraldi PG, Giovannini MG, Pedata F. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Res 1073-1074: 470-480, 2006.
38. Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA. Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke 34:2483-2488, 2003.
39. Zhu Y, Mao XO, Sun Y, Xia Z, Greenberg DA. p38 Mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J Biol Chem 277:22909-22914, 2002.
40. Morel S, Milano G, Ludunge KM, Corno AF, Samaja M, Fleury S, Bonny C, Kappenberger L, von Segesser LK, Vassalli G. Brief reoxygenation episodes during chronic hypoxia enhance posthypoxic recovery of LV function: role of mitogen-activated protein kinase signaling pathways. Basic Res Cardiol 101:336-345, 2006.
41. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Md AB, Galie N. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100:131-138, 2005.
42. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 280:20995-21003, 2005.
43. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319:991-997, 2006.
44. Zhuang S, Yan Y, Daubert RA, Han J, Schnellmann RG. ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am J Physiol Renal Physiol 292:F440-F447, 2007.
45. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 281:21256-21265, 2006.
46. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, Smolenski A, Lohmann SM, Wollert KC. cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 281:32831-32840, 2006.
47. De Chiara G, Marcocci ME, Torcia M, Lucibello M, Rosini P, Bonini P, Higashimoto Y, Damonte G, Armirotti A, Amodei S, Palamara AT, Russo T, Garaci E, Cozzolino F. Bcl-2 phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem 281:21353-21361, 2006.